Clinical Trials Search Results

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Positive Breast Cancer

REPLATINUM: A Phase 3, Controlled, Open-label,Randomized Study of RRx-001 Administered Sequentially with a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer

A Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization in Patients with Localized Prostate Carcinoma and Obstructive Lower Urinary Tract Symptoms

Phase Ib Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors for Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations

Phase 2, Single Arm Study of Luspatercept for the Treatment of Anemia in lower Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Myelodysplastic Syndromes/Myeloproliferative Neoplasms (MDS/MPN)

A Phase 3 (Pivotal Stage) Study of NBTXR3 Activated by Investigators Choice of Radiotherapy Alone or Radiotherapy in Combination with Cetuximab for Platinum-based Chemotherapy-ineligible Elderly Patients with Locally Advanced Head & Neck Squamous Cell Carcinoma

A Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)

A Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients with Advanced Hematologic and Solid Tumor Malignancies

Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).

A phase 1, open-label, multicentre, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma (ASPEN-07)

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)